Page last updated: 2024-09-05

sorafenib and crenolanib

sorafenib has been researched along with crenolanib in 11 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(crenolanib)
Trials
(crenolanib)
Recent Studies (post-2010) (crenolanib)
6,5207305,25167464

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)crenolanib (IC50)
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)0.79
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0089

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (45.45)24.3611
2020's6 (54.55)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bensinger, D; Cremer, A; Engemann, V; Kohl, V; Schmidt, B; Schmitz, K; Stegmaier, K; Stubba, D; Stuckert, J; Waßmer, T1
Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S1
Demizu, Y; Inoue, T; Naito, M; Ohki, H; Ohoka, N; Suzuki, M; Tsuji, G; Tsukumo, Y; Uchida, T; Yoshida, M1
Baker, SD; Buaboonnam, J; Hu, S; Inaba, H; Janke, LJ; Orwick, S; Ramachandran, A; Roberts, MS; Stewart, CF; Turner, DC; Zimmerman, EI1
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F1
Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J1
Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK1
Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J1
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM1
Baker, SD; Blachly, JS; Buelow, DR; Inaba, H; Li, L; Panetta, JC; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, S; van Oosterwijk, JG1

Reviews

3 review(s) available for sorafenib and crenolanib

ArticleYear
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine

2014
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Leukemia, 2020, Volume: 34, Issue:3

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome

2020
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Minerva medica, 2020, Volume: 111, Issue:5

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine

2020

Other Studies

8 other study(ies) available for sorafenib and crenolanib

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.
    Journal of medicinal chemistry, 2019, 03-14, Volume: 62, Issue:5

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Embryo, Nonmammalian; fms-Like Tyrosine Kinase 3; High-Throughput Screening Assays; Humans; Molecular Docking Simulation; Mutation; Prospective Studies; Protein Kinase Inhibitors; Zebrafish

2019
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Bioorganic & medicinal chemistry, 2022, 02-15, Volume: 56

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship

2022
Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein.
    ACS medicinal chemistry letters, 2022, Dec-08, Volume: 13, Issue:12

    Topics:

2022
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Blood, 2013, Nov-21, Volume: 122, Issue:22

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Xenograft Model Antitumor Assays

2013
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
    British journal of haematology, 2019, Volume: 187, Issue:4

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines

2019
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:5

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase

2020
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 06-13, Volume: 28, Issue:12

    Topics: Antineoplastic Agents; Benzimidazoles; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Phenylurea Compounds; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Sorafenib

2022